Company Overview

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of differentiated immuno-oncology therapies for patients with cancer. The company operates within the biotechnology and pharmaceutical research industry, with a strategic emphasis on targeting key resistance pathways in tumor immunology. Arcus does not currently market approved products and generates limited revenue primarily from collaboration and licensing arrangements.

The company’s core value proposition is its rational, pathway-driven drug design platform, which aims to develop best-in-class or first-in-class small molecules and antibodies that can be combined across multiple tumor types. Arcus was founded in 2015 by experienced oncology drug developers and built its pipeline through in-house research rather than acquisitions, enabling tight integration of scientific strategy and clinical development.

Business Operations

Arcus’s operations are centered on drug discovery, preclinical research, and clinical development, with its pipeline spanning multiple immuno-oncology mechanisms. Key business segments include antibody-based checkpoint inhibitors and small-molecule pathway inhibitors, with lead programs targeting TIGIT, PD-1, adenosine signaling, CD73, and HIF-2α. The company’s most advanced programs include zimberelimab, domvanalimab, etrumadenant, quemliclustat, and casdatifan, all of which are in clinical development.

The company conducts clinical trials globally but maintains lean internal operations, outsourcing manufacturing and portions of clinical execution to contract research and manufacturing organizations. Arcus maintains a significant strategic collaboration with Gilead Sciences, Inc., which supports development funding and global commercialization potential while allowing Arcus to retain substantial co-development and co-commercialization rights in the United States for select assets.

Strategic Position & Investments

Arcus’s strategy focuses on building combination immunotherapy regimens by advancing multiple internally discovered assets that can be rationally combined based on tumor biology. A cornerstone of this strategy is its long-term collaboration with Gilead Sciences, Inc., which includes equity investments, upfront payments, and shared development costs for several programs, notably domvanalimab and zimberelimab.

The company continues to invest heavily in expanding its clinical pipeline across lung, gastrointestinal, renal, and other solid tumors, while also advancing novel mechanisms such as HIF-2α inhibition through casdatifan. Arcus has not pursued a diversified acquisition strategy; instead, it allocates capital primarily toward internal R&D and late-stage clinical trials to maximize long-term value creation.

Geographic Footprint

Arcus Biosciences is headquartered in Hayward, California, and its primary operations are based in the United States. The company’s research and development activities are largely U.S.-centric, supported by a network of domestic and international contractors.

Despite its limited physical footprint outside the U.S., Arcus has a growing global clinical and strategic presence through multinational clinical trials and its partnership with Gilead Sciences, Inc., which provides international development and commercialization capabilities across North America, Europe, and Asia-Pacific markets.

Leadership & Governance

Arcus was founded and continues to be led by executives with deep experience in oncology drug development, emphasizing scientific rigor, capital discipline, and long-term value creation. The leadership team maintains significant ownership stakes, aligning management incentives with shareholder outcomes.

Key executives include:

• Terry Rosen, PhD – Co-Founder, Chief Executive Officer
• Juan Jaen, PhD – Chief Scientific Officer
• Robert C. Goeltz – Chief Financial Officer
• Jennifer Jarrett – Chief Operating Officer
• Douglas Murray, MD – Chief Medical Officer

The board and executive team collectively emphasize a strategy of focused pipeline development, selective partnering, and maintaining operational flexibility through clinical-stage growth.